Immediate Impact
48 standout
Citing Papers
CAR T therapies in multiple myeloma: unleashing the future
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Tzu‐Min Yeh being referenced
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
2022
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Tzu‐Min Yeh | 329 | 211 | 220 | 38 | 488 | |
| Xingbing Wang | 291 | 153 | 156 | 53 | 572 | |
| Rafael Martínez | 134 | 209 | 237 | 26 | 557 | |
| Emilia Salzmann‐Manrique | 173 | 194 | 75 | 34 | 504 | |
| Anthony S. Kurec | 67 | 158 | 96 | 32 | 479 | |
| Qu Cui | 145 | 44 | 116 | 36 | 507 | |
| Carlos Eduardo Coral de Oliveira | 208 | 58 | 193 | 39 | 518 | |
| Haizhou Xing | 195 | 156 | 182 | 28 | 520 | |
| Michel Heenen | 179 | 57 | 173 | 38 | 514 | |
| C. Matthias Wilk | 134 | 245 | 126 | 29 | 495 | |
| Alden Chesney | 102 | 156 | 125 | 39 | 506 |
All Works
Loading papers...